Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
IF:
1.3
5-Year IF:
2.6
Eigenfactor:
0.00079
JCI:
0.24
SJR:
0.429
SNIP:
0.287
CiteScore™::
2.7
H-Index:
81
Indexed in
Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model
Get access
ABSTRACT
In the development of targeted cancer immunotherapies, the choice of antigen is obviously critical to the design of any therapeutic strategy, but particularly so for tumor vaccines, which must distinguish malignant cells from normal cells. Investigations a decade ago focused on mutated tumor antigens, or viral tumor antigens, with the belief that these foreign or abnormal proteins would be best recognized by the host immune system.Within the last 10 years, however, several tumor antigens have been identified on the basis of recognition by infiltrating T cells in tumor samples. Studies on melanoma, in particular, have revealed that in addition to some mutated tumor antigens, several aberrantly expressed normal proteins, as well as tissue-specific differentiation factors, are recognized by the host immune system. Similar studies in other solid tumors have revealed that certain oncogenes overexpressed in malignant cells, such as p53 and HER-2/neu, are also recognized by host T cells. Our group has been investigating the HER-2/neu oncogenic protein as a vaccine target in patients with HER-2/neu–overexpressing cancers. However, several issues unique to the design of human clinical trials of cancer vaccines must be addressed when translating preclinical experiments to human clinical trials. First, HER-2/neu protein expression can vary depending on the tumor type. How would expression differences impact clinical trial design? Secondly, what are the issues in clinical trial design that are critical to the successful execution of a phase I study of a peptide-based vaccine? Thirdly, what types and amounts of clinical material are readily available for immunologic analysis and can be obtained with little distress and risk to the patients enrolled in the study? Finally, what steps must be implemented for a laboratory assay to evolve to meet the validation criteria needed for application as an immunologic monitoring tool?
-
Di Jiabo, Massuger Leon F.A.G., Duiveman-de Boer Tjitske, Zusterzeel Petra L.M., Figdor Carl G, Torensma Ruurd, Functional OCT4-specific CD4+and CD8+T cells in healthy controls and ovarian cancer patients, OncoImmunology, 2, 5, 2013. Crossref
-
Muller Claude P., Putz Mike M., Peptide Vaccines, in Topley & Wilson's Microbiology and Microbial Infections, 2010. Crossref
-
NELSON PETER S., Identifying Immunotherapeutic Targets for Prostate Carcinoma through the Analysis of Gene Expression Profiles, Annals of the New York Academy of Sciences, 975, 1, 2002. Crossref
-
Madhusudan Srinivasan, Ganesan Trivadi S., Tyrosine kinase inhibitors in cancer therapy, Clinical Biochemistry, 37, 7, 2004. Crossref
-
Kiessling Rolf, Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., Seliger B., , 85, 2002. Crossref
-
Cruz Jay S.Dela, Lau Suk Ying, Ramirez Ernesto M, Giovanni Carla De, Forni Guido, Morrison Sherie L, Penichet Manuel L, Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice, Vaccine, 21, 13-14, 2003. Crossref
-
Sette Alessandro, Fikes John, Epitope-based vaccines: an update on epitope identification, vaccine design and delivery, Current Opinion in Immunology, 15, 4, 2003. Crossref
-
Díez-Rivero Carmen M., Reche Pedro, Discovery of Conserved Epitopes Through Sequence Variability Analyses, in Bioinformatics for Immunomics, 2009. Crossref
-
Smith Susan E., Stopeck Alison T., Vaccine Therapy for Breast and Ovarian Cancers, in Handbook of Cancer Vaccines, 2004. Crossref
-
Disis Mary L., Schiffman Kathy, Guthrie Katherine, Salazar Lupe G., Knutson Keith L., Goodell Vivian, dela Rosa Corazon, Cheever Martin A., Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein—Based Vaccine, Journal of Clinical Oncology, 22, 10, 2004. Crossref
-
Kalli Kimberly R., Krco Christopher J., Hartmann Lynn C., Goodman Karin, Maurer Matthew J., Yu Chao, Johnson Elliot M., Erskine Courtney L., Disis Mary L., Wettstein Peter J., Fikes John D., Beebe Melanie, Ishioka Glenn, Knutson Keith L., An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with Cancer, Cancer Research, 68, 12, 2008. Crossref